Overview
Curetopia is a decentralized-science (DeSci) research collective — a BioDAO that uses on-chain governance and tokenized intellectual property to fund cures for rare diseases. It describes itself as “community medicine”: patient communities and their allies collectively decide which research to back, and the resulting IP is owned by the community rather than a single sponsor.
Curetopia is the first BioDAO to run a community auction on Solana, and was incubated through the Bio Protocol launchpad. It is led by Dr. Ethan Perlstein — a Harvard PhD and Y Combinator alum who previously founded a biotech that advanced a rare-disease drug into Phase 3 trials — placing an experienced drug developer at the head of a patient-owned research organization.
The rare-disease funding gap
More than 10,000 rare diseases collectively affect roughly 1 in 10 people globally, yet the overwhelming majority have no approved treatment. Each individual disease has a small patient population — an estimated $200–300M addressable market per condition — so traditional pharma, optimized for blockbuster indications, systematically under-invests in them. The unmet need is enormous in aggregate (a $1 trillion-plus economic burden in the U.S. alone) but fragmented into thousands of markets each too small to attract conventional capital.
Curetopia's answer is to pool that fragmented demand. Patients, families and researchers who each care intensely about one rare condition coordinate through a shared treasury and governance token, and the DAO concentrates on the highest-leverage opportunities — beginning with drug repurposing for inherited metabolic diseases, where an already-approved molecule can reach patients far faster and more cheaply than a new chemical entity. This is the same patient-directed funding thesis that VitaDAO pioneered for longevity, applied to the long tail of orphan conditions.
The $CURES token and governance
Curetopia is coordinated by the $CURES token on Solana, with a maximum supply of 100,000,000. Governance is token-weighted at one vote per token: proposals are posted publicly, discussed by the community, and then voted on by $CURES holders. Roughly 15% of supply was distributed through the community auction, with the remainder allocated across the core team, treasury reserves and contributor incentives.
What distinguishes Curetopia's design is that the token is also a contribution reward. Curetopians who supply data of any kind, biospecimens, clinical-trial participation, or even compute time for analysis earn $CURES — so the people who materially advance the research also accumulate governance rights over it. Smart contracts attach “use-it-or-lose-it” commitments to shared data and cell lines, unlocking token rewards only when a resource is actually put to work. It is a DAO-tokenomics model built to align voting power with genuine scientific contribution, not merely with capital.
AARS2, IP-NFTs and community medicines
Curetopia tokenizes the research it funds as IP-NFTs through Molecule: a patent or research program is minted on-chain and can be fractionally owned, so provenance and licensing are auditable by anyone — including the patient communities themselves. When tokenized IP leads to an approved drug, the resulting revenue flows back to the Curetopia treasury as “community medicines” owned by the DAO rather than a private licensor.
The model has already produced a concrete result. Curetopia identified a potential treatment for AARS2 — a fatal rare disease with no approved therapy — and moved to file a provisional patent on the findings and tokenize it, with proceeds directed back to the DAO. It is exactly the loop the structure is meant to close: community-funded discovery becoming community-owned IP whose upside returns to the patients who backed it.
Place in the Bio Protocol ecosystem
Curetopia sits alongside VitaDAO (longevity), HairDAO (hair loss), CryoDAO (cryopreservation), ValleyDAO (synthetic biology) and Cerebrum DAO (brain health) in the Bio Protocol portfolio of BioDAOs. It was one of three projects — with Long COVID Labs and Quantum Biology DAO — admitted early to Bio Incubator Cohort 2.
Its $1.77M community raise from 1,000+ individual funders in March 2025 made it a notable proof point for the Solana DeSci thesis and for Bio Protocol's launchpad, and it has since partnered with initiatives such as MIRA to widen its reach into rare-disease patient networks.
How Caper approaches this
Curetopia rewards the people who do the work — contributing data, biospecimens or trial participation earns $CURES, and $CURES is governance. That instinct, tying influence to contribution, is the same one a caper builds in at the protocol level. The difference is what happens after the token is minted: $CURES trades freely at one vote per token, so a large enough buyer on the open market can accumulate a decisive say over which rare-disease research gets funded, regardless of whether they ever contributed.
On Caper, a member's influence is the canonical vote weight (t·v)/(V·T) — governance holdings t multiplied by an earned, soulbound proof-of-vote record v (verified in contracts/src/caper_dao.rs: compute_vote_weight returns (held·votes)/(supply·circulation); the vote token is minted one-per-vote at DIVISIBILITY_NONE with a depositor rule of global_caller and depositor_updater set to deny_all, which makes it non-transferable). The same formula sets a member's treasury exit share, and exit() reuses that exact weight before burning the tokens. A big bag still counts — t is a multiplier, not bagless — but the decisive part of governance is participation nobody can purchase. For a patient community deciding whose cure to back, that keeps control with the people the science is actually for.